drugset
drugset / Trial / NCT00098514

Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

NCT00098514 ↗

Phase 1 Completed 53 enrolled Dana-Farber Cancer Institute National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying side effects, best way to give, and best dose of talotrexin in treating patients with advanced or recurrent solid tumors.

Timeline

Start
2003-12
Primary completion
2007-03
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject talotrexin Unknown 3.33 mg/m2 Intravenous
Subject talotrexin Unknown 5 mg/m2 Intravenous
Subject talotrexin Unknown 6.7 mg/m2 Intravenous
Subject talotrexin Unknown 7.5 mg/m2 Intravenous
Subject talotrexin Unknown 9 mg/m2 Intravenous
Subject talotrexin Unknown 10 mg/m2 Intravenous
Subject talotrexin Unknown 11.25 mg/m2 Intravenous
Subject talotrexin Unknown 12 mg/m2 Intravenous
Subject talotrexin Unknown 17 mg/m2 Intravenous

Indications

cancer of unknown primary site